A Phase 3 interventional study of Placebo and Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Active, not recruiting at 193 sites in 24 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one has the largest enrollment, is one of 4 that started in 2018, is one of 12 in phase 3, and was the 2nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
RenJi Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,533 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 272 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
34 studies in Dermatitis, Atopic by AbbVie: 3 open now, 12 under way, 4 of them phase 3. Of 19 finished, 8 (42%) have results posted.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one has the largest enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2018, is one of 12 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 2nd registered.
AbbVie’s Dermatitis, Atopic studies by the year they started, since 2016.
3 of the studies testing upadacitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT07678645RenJi HospitalThe Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, from their registry updates:
Among AbbVie’s 34 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, a blinded Long-term Extension (LTE) Period after Week 260 to Week 524, and a 30-day follow-up visit. Participants who meet eligibility criteria in the Main Study will be randomly assigned in a 1:1:1 ratio to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo once daily, in combination with topical corticosteroids.
Upon completion of enrollment of 810 participants in the Main Study, a supplemental study will continue to enroll adolescent participants (Adolescent Sub-study) until a total of 180 adolescent participants are enrolled in the overall study (Main Study + Adolescent Sub-study).
Approximately 1000 participants from M16-045 or M18-891 and approximately 500 participants from M16-047 will have the opportunity to enroll into the blinded Long-Term Extension (LTE) period (Week 260 - Week 524) after reaching Week 260 in their respective studies.
Randomization for the Main Study will be stratified by Baseline disease severity (validated Investigator Global Assessment Scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the Adolescent Sub-study will be stratified by Baseline disease severity (moderate [vIGA-AD 3] versus severe [vIGA-AD 4]) and by geographic region (US/Puerto Rico/Canada and Other).
At Week 16 of both the Main Study and the Adolescent Sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period, and participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose. For the Main Study, the re-randomization will be stratified by Eczema Area and Severity Index (EASI) 50 responder status (Yes/No), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other) and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). For the Adolescent Sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other).
Starting at Week 4, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary The Primary Analysis for the Main Study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the Main Study and the Adolescent Sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Drug: Placebo · Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)
Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)
Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)
Participants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524.
Drug: Upadacitinib · Drug: Topical corticosteroids (TCS)
Tablets taken orally once a day
Tablets taken orally once a day
Also known as: ABT-494, RINVOQ™
Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity. Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 4
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 2
Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
Time frame: Baseline and Week 4
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a ranked secondary endpoint for participants in the Upadacitinib 30 mg + Topical Corticosteroids group versus Placebo + Topical Corticosteroids group only.
Time frame: Baseline and Week 16
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Main Study: Percent Change From Baseline in EASI Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 4
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 2
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
Time frame: Baseline and Week 4
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
EASI is used to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. and the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a secondary endpoint for participants in the Upadacitinib 30 mg + TCS group versus Placebo + TCS group only.
Time frame: Baseline and Week 16
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16
Adolescents: Percent Change From Baseline in EASI Score at Week 16
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
Time frame: Baseline and Week 16
Participants were enrolled at 171 clinical sites in 22 countries in the Asia-Pacific region, Europe, Middle East, North America, and Oceania. The study included a 16-week double-blind treatment period followed by a blinded extension period (ongoing). The first 810 adults and adolescents enrolled constituted the Main Study; additional adolescents were enrolled in the Adolescent Substudy to ensure enrollment of a total of 180 adolescent participants overall. Results are reported up to Week 16.
| Milestone | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|---|---|---|
| Started | 264 | 261 | 260 | 63 | 60 | 60 |
| Received study drug | 264 | 261 | 260 | 62 | 60 | 60 |
| Completed | 244 | 249 | 250 | 59 | 58 | 60 |
| Not completed | 20 | 12 | 10 | 4 | 2 | 0 |
| Withdrew: Adverse event | 3 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 5 | 2 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 | 2 | 2 | 1 | 0 |
| Withdrew: Other | 3 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Ongoing at time of analysis | 5 | 3 | 2 | 1 | 0 | 0 |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 | 26.4 (21.5 to 31.4) | 64.6 (59.1 to 70.0) | 77.1 (72.3 to 81.9) |
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 | 10.9 (7.4 to 14.4) | 39.6 (34.1 to 45.2) | 58.6 (53.0 to 64.2) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16 | 15.0 (10.9 to 19.0) | 51.7 (46.0 to 57.5) | 63.9 (58.4 to 69.4) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16 | 13.2 (9.4 to 17.0) | 42.8 (37.2 to 48.4) | 63.1 (57.6 to 68.6) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4 | 15.0 (10.9 to 19.0) | 52.4 (46.7 to 58.2) | 65.6 (60.2 to 71.1) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4 | 14.8 (10.8 to 18.8) | 58.7 (53.1 to 64.2) | 72.4 (67.3 to 77.5) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2 | 6.9 (4.1 to 9.8) | 31.0 (25.8 to 36.2) | 44.1 (38.5 to 49.8) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4 | 4.9 (2.5 to 7.4) | 28.3 (23.2 to 33.4) | 43.8 (38.1 to 49.4) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a ranked secondary endpoint for participants in the Upadacitinib 30 mg + Topical Corticosteroids group versus Placebo + Topical Corticosteroids group only.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16 | 1.3 (0.0 to 2.6) | 12.0 (8.3 to 15.7) | 22.6 (17.8 to 27.3) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1 | 3.1 (1.1 to 5.0) | 12.2 (8.4 to 15.9) | 19.2 (14.7 to 23.8) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
| percent change | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16 | -25.07 (-31.64 to -18.49) | -58.14 (-64.24 to -52.05) | -66.85 (-72.99 to -60.72) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
| percent change | Placebo + Topical Corticosteroids | Upadacitinib 15 mg + Topical Corticosteroids | Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Main Study: Percent Change From Baseline in EASI Score at Week 16 | -45.86 (-50.09 to -41.63) | -77.99 (-81.87 to -74.10) | -87.31 (-91.20 to -83.41) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16 | 30.3 (18.9 to 41.6) | 63.3 (51.1 to 75.5) | 84.3 (74.9 to 93.6) |
The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 | 11.2 (3.4 to 19.1) | 38.3 (26.0 to 50.6) | 67.4 (55.5 to 79.4) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16 | 21.3 (11.0 to 31.6) | 45.6 (32.7 to 58.5) | 51.8 (38.7 to 64.9) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16 | 20.7 (10.7 to 30.7) | 48.3 (35.7 to 61.0) | 73.6 (62.3 to 84.8) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4 | 23.0 (12.4 to 33.5) | 45.6 (32.7 to 58.5) | 46.4 (33.4 to 59.5) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4 | 28.6 (17.4 to 39.7) | 54.9 (42.3 to 67.5) | 78.3 (67.9 to 88.8) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2 | 9.5 (2.3 to 16.8) | 33.7 (21.7 to 45.8) | 51.7 (39.0 to 64.3) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4 | 9.5 (2.3 to 16.8) | 34.2 (22.1 to 46.3) | 45.0 (32.4 to 57.6) |
EASI is used to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. and the severity score is calculated as the sum of the intensity scores (scored from 0 \[none\], to 3 \[severe\]) for redness, thickness, scratching, and lichenification. The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score. The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a secondary endpoint for participants in the Upadacitinib 30 mg + TCS group versus Placebo + TCS group only.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16 | 4.8 (0.0 to 10.0) | 13.3 (4.7 to 21.9) | 25.0 (14.0 to 36.0) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.
| percentage of participants | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1 | 9.8 (2.4 to 17.3) | 8.8 (1.4 to 16.1) | 16.1 (6.5 to 25.7) |
Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.
| percent change | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16 | -32.96 (-49.87 to -16.05) | -59.34 (-75.78 to -42.90) | -49.02 (-65.35 to -32.69) |
EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.
| percent change | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|
| Adolescents: Percent Change From Baseline in EASI Score at Week 16 | -53.53 (-61.23 to -45.82) | -77.90 (-85.36 to -70.44) | -89.22 (-96.49 to -81.95) |
Collected over From first dose of study drug up to Week 16, or 30 days after last dose for participants who did not enter the blinded extension period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adults: Placebo + Topical Corticosteroids | 0/264 (0%) | 9/264 (3.4%) | 99/264 (37.5%) |
| Adults: Upadacitinib 15 mg + Topical Corticosteroids | 0/261 (0%) | 7/261 (2.7%) | 111/261 (42.5%) |
| Adults: Upadacitinib 30 mg + Topical Corticosteroids | 0/260 (0%) | 4/260 (1.5%) | 123/260 (47.3%) |
| Adolescents: Placebo + Topical Corticosteroids | 0/62 (0%) | 0/62 (0%) | 21/62 (33.9%) |
| Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | 0/60 (0%) | 1/60 (1.7%) | 24/60 (40%) |
| Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | 0/60 (0%) | 0/60 (0%) | 32/60 (53.3%) |
| Event | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|---|---|---|
| LIGAMENT RUPTUREInjury, poisoning and procedural complications | 0/264 | 0/261 | 0/260 | 0/62 | 1/60 | 0/60 |
| PANCYTOPENIABlood and lymphatic system disorders | 0/264 | 0/261 | 1/260 | 0/62 | 0/60 | 0/60 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 0/264 | 0/261 | 1/260 | 0/62 | 0/60 | 0/60 |
| ANAPHYLACTIC REACTIONImmune system disorders | 1/264 | 0/261 | 1/260 | 0/62 | 0/60 | 0/60 |
| ADENOCARCINOMA OF COLONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/264 | 0/261 | 1/260 | 0/62 | 0/60 | 0/60 |
| RETINAL DETACHMENTEye disorders | 0/264 | 1/261 | 0/260 | 0/62 | 0/60 | 0/60 |
| APPENDICITISInfections and infestations | 0/264 | 1/261 | 0/260 | 0/62 | 0/60 | 0/60 |
| PERITONSILLAR ABSCESSInfections and infestations | 0/264 | 1/261 | 0/260 | 0/62 | 0/60 | 0/60 |
| PHARYNGITIS STREPTOCOCCALInfections and infestations | 0/264 | 1/261 | 0/260 | 0/62 | 0/60 | 0/60 |
| OVERDOSEInjury, poisoning and procedural complications | 0/264 | 1/261 | 0/260 | 0/62 | 0/60 | 0/60 |
| Event | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids |
|---|---|---|---|---|---|---|
| ACNESkin and subcutaneous tissue disorders | 6/264 | 25/261 | 36/260 | 1/62 | 8/60 | 9/60 |
| NASOPHARYNGITISInfections and infestations | 31/264 | 31/261 | 37/260 | 3/62 | 6/60 | 3/60 |
| ORAL HERPESInfections and infestations | 5/264 | 9/261 | 22/260 | 1/62 | 2/60 | 1/60 |
| HEADACHENervous system disorders | 12/264 | 11/261 | 11/260 | 4/62 | 5/60 | 4/60 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 21/264 | 20/261 | 19/260 | 1/62 | 1/60 | 4/60 |
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 18/264 | 8/261 | 2/260 | 4/62 | 3/60 | 0/60 |
| VOMITINGGastrointestinal disorders | 2/264 | 1/261 | 0/260 | 1/62 | 1/60 | 4/60 |
| PYREXIAGeneral disorders | 3/264 | 5/261 | 3/260 | 0/62 | 0/60 | 4/60 |
| DIARRHOEAGastrointestinal disorders | 4/264 | 10/261 | 9/260 | 4/62 | 1/60 | 3/60 |
| STAPHYLOCOCCAL SKIN INFECTIONInfections and infestations | 1/264 | 1/261 | 1/260 | 4/62 | 0/60 | 1/60 |
All randomized participants
| Age, Continuous(years) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| Mean | 37.2 ± 14.08 | 35.0 ± 13.29 | 38.3 ± 14.82 | 15.1 ± 1.85 | 15.4 ± 1.65 | 15.3 ± 1.86 | 32.8 ± 15.29 |
| Age, Customized(Participants) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| 12 - 14 years | 0 | 0 | 0 | 23 | 14 | 21 | 58 |
| 15 - 17 years | 0 | 0 | 0 | 40 | 46 | 39 | 125 |
| 18 - < 40 years | 156 | 176 | 158 | 0 | 0 | 0 | 490 |
| 40 - < 65 years | 94 | 80 | 85 | 0 | 0 | 0 | 259 |
| ≥ 65 years | 14 | 5 | 17 | 0 | 0 | 0 | 36 |
| Sex: Female, Male(Participants) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| Female | 101 | 104 | 95 | 36 | 27 | 25 | 388 |
| Male | 163 | 157 | 165 | 27 | 33 | 35 | 580 |
| Ethnicity (NIH/OMB)(Participants) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 15 | 21 | 14 | 7 | 8 | 7 | 72 |
| Not Hispanic or Latino | 249 | 240 | 246 | 56 | 52 | 53 | 896 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 | 0 | 0 | 0 | 6 |
| Asian | 52 | 57 | 58 | 14 | 13 | 6 | 200 |
| Native Hawaiian or Other Pacific Islander | 0 | 3 | 1 | 0 | 0 | 0 | 4 |
| Black or African American | 15 | 15 | 9 | 5 | 5 | 6 | 55 |
| White | 196 | 177 | 188 | 44 | 41 | 46 | 692 |
| More than one race | 0 | 7 | 1 | 0 | 1 | 2 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Study Enrollment(Participants) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| Main Study | 264 | 261 | 260 | 40 | 39 | 37 | 901 |
| Adolescent Substudy | 0 | 0 | 0 | 23 | 21 | 23 | 67 |
| Geographic Region(Participants) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| US/Puerto Rico/Canada | 90 | 90 | 89 | 31 | 31 | 31 | 362 |
| Japan | 18 | 16 | 17 | 0 | 0 | 0 | 51 |
| China | 16 | 15 | 15 | 2 | 2 | 1 | 51 |
| Other | 140 | 140 | 139 | 30 | 27 | 28 | 504 |
| Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD)(Participants) | Adults: Placebo + Topical Corticosteroids | Adults: Upadacitinib 15 mg + Topical Corticosteroids | Adults: Upadacitinib 30 mg + Topical Corticosteroids | Adolescents: Placebo + Topical Corticosteroids | Adolescents: Upadacitinib 15 mg + Topical Corticosteroids | Adolescents: Upadacitinib 30 mg + Topical Corticosteroids | Total |
|---|---|---|---|---|---|---|---|
| 3 (Moderate) | 123 | 124 | 123 | 28 | 29 | 29 | 456 |
| 4 (Severe) | 141 | 137 | 137 | 35 | 31 | 31 | 512 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 193 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Aug 2018 to primary completion in Feb 2021, 30 months.
Results were first posted in Mar 2022, 1 year 1 month after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 30 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Upadacitinib · Topical Corticosteroid